The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multidisciplinary immune-related toxicity (IR-Tox) program for immune-related adverse events: A two-year experience.
 
Aanika Balaji
No Relationships to Disclose
 
Jiajia Zhang
No Relationships to Disclose
 
Karthik Suresh
No Relationships to Disclose
 
Jenna Mammen
Stock and Other Ownership Interests - Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Five Prime Therapeutics
 
Joanna Melia
Research Funding - Seres Therapeutics (Inst)
 
Amy K. Kim
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
 
Meghan Berkenstock
No Relationships to Disclose
 
Inbal Sander
No Relationships to Disclose
 
Jose Manuel Monroy-Trujillo
No Relationships to Disclose
 
Lyle Wilfred Ostrow
No Relationships to Disclose
 
Joanne Riemer
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Evan J. Lipson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Macrogenics; Merck; Millennium; Novartis; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst); Sysmex (Inst)
Patents, Royalties, Other Intellectual Property - METHOD OF PREVENTING ORGAN TRANSPLANT REJECTIONS USING AGONISTS TO THE PD-1 CHECKPOINT PATHWAY (Inst)
 
Patrick M. Forde
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)
 
William Howard Sharfman
Honoraria - Array BioPharma; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; ION Pharma; Merck; Novartis; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Merck; Novartis
 
Julie R. Brahmer
Honoraria - Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Janssen Oncology; Lilly; Merck; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Revolution; Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Janssen Oncology; merck
 
Laura Cappelli
Consulting or Advisory Role - Regeneron
Research Funding - Bristol-Myers Squibb
 
Jarushka Naidoo
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb